Drug Type Small molecule drug |
Synonyms 克利加巴林, HSK 16149, HSK-16149 + [2] |
Target |
Action blockers |
Mechanism CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (15 May 2024), |
Regulation- |
Molecular FormulaC12H19NO2 |
InChIKeyWCEFMBSFXJUREW-LIJGXYGRSA-N |
CAS Registry2209104-84-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuralgia, Postherpetic | China | 28 Jun 2024 | |
Diabetic peripheral neuropathic pain | China | 15 May 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuralgia | Phase 3 | - | 30 May 2024 | |
Peripheral neuralgia | Phase 3 | China | 17 Feb 2022 | |
Pain, Postoperative | Phase 2 | China | 08 Mar 2023 | |
Post-herpetic neuritis | Phase 1 | China | 20 Mar 2023 | |
Renal Insufficiency | Phase 1 | China | 12 Dec 2022 | |
Diabetic peripheral neuropathy | Phase 1 | China | 01 Apr 2021 | |
Diabetic Neuropathies | Phase 1 | China | 28 Dec 2018 | |
Fibromyalgia | IND Approval | China | 17 Apr 2024 |
NCT06122012 (ADA2024) Manual | Phase 2 | 134 | Crisugabalin with Acetyl-Levo-Carnitine | fwqpnuygcq(aomptbmugs) = fwkslyfhuf ffpqzjbblm (ulaydzbmff ) | Positive | 21 Jun 2024 | |
lipoic acid (LA) combined with acetyl-levo-carnitine | fwqpnuygcq(aomptbmugs) = ynavabsxxx ffpqzjbblm (ulaydzbmff ) | ||||||
Phase 2/3 | 301 | Crisugabalin Besilate 40mg | vwojfipnun(aqitjswonf) = 86.4% subjects experienced a total of 1095 Treatment Emergent Adverse Events (TEAEs) during the study, including 203 drug-related TEAEs with the incidence of 38.9% nsjzpggeer (eehnblzcok ) View more | Positive | 14 Jun 2024 | ||
Not Applicable | - | Placebo | enrzdcqevq(muxqxhaewg) = ozzuknscyh ebuqkjjqvc (tlxjoeqwth ) | Positive | 20 Jun 2023 | ||
enrzdcqevq(muxqxhaewg) = rbiqhbtgau ebuqkjjqvc (tlxjoeqwth ) |